AD Biostatistics Late Stage Oncology
Jersey City
Permanent
USD200000 - USD240000
Research and Development
PR/588915_1776428786
AD Biostatistics Late Stage Oncology
Associate Director, Biostatistics (Oncology / Late Stage)
Salary: 200-240,000 base, 20% bonus + equity | additional benefits
We are seeking a highly motivated Associate Director, Biostatistics to provide statistical leadership across clinical development programs. In this role, you will partner closely with cross‑functional teams to shape study design, drive rigorous data analysis, and support evidence‑based decision making across late‑stage clinical trials.
This position is based in New Jersey and requires a minimum of three days on site per week to support team collaboration, operational excellence, and anticipated organizational growth.
Key Responsibilities
- Lead statistical strategy for clinical trials, including study design, endpoints, sample size determination, and analysis methodologies
- Author and oversee Statistical Analysis Plans (SAPs) and interpret complex clinical data to deliver actionable insights
- Provide statistical input into regulatory submissions and key health authority interactions
- Partner with Clinical, Regulatory, and R&D teams as a strategic thought leader in late‑stage development
- Drive adoption of advanced statistical methods, tools, and best practices, including innovative trial designs
Qualifications
- PhD in Statistics, Biostatistics, or related discipline with 6+ years of experience in clinical research and drug development
- Strong expertise in R and/or SAS, with experience producing tables, listings, and figures
- Deep understanding of ICH, FDA, and global regulatory requirements
- Demonstrated leadership and experience guiding statistical teams
- Exposure to oncology clinical development strongly preferred
- Experience with Bayesian methods and adaptive trial designs
- Excellent communication skills with the ability to translate complex analyses to non‑technical audiences
- Record of scientific contributions, including peer‑reviewed publications, is a plus
